27 January 2014: Articles
Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration
Unusual clinical course, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Timothy Larsen ABCDEFG , Alehegn Gelaye ABCDEFG , Christopher Durando ABCDEFGDOI: 10.12659/AJCR.889866
Am J Case Rep 2014; 15:45-48
Background
Warfarin is the most commonly prescribed oral anticoagulant in the management of thromboembolic disease [1]. Warfarin has a narrow therapeutic window which necessitates frequent monitoring and dose adjustments in order to remain therapeutic. Many medications are known to interact with warfarin resulting in either over or under anticoagulation [2,3]. Over anticoagulation increases the risk of major bleeding. Concomitant administration of antibiotics along with warfarin is associated with a high risk of over anticoagulation. Bleeding is the most clinically important complication associated with over anticoagulation [4]. Hereinwe present a case of a 53-year-old man who presented with significant, severe bleeding from a tooth extraction after he was treated with amoxicillin/clavulanate while on warfarin.
Case Report
A 53-year-old Caucasian male with a past medical history of protein C deficiency, recurrent deep vein thrombosis, and pulmonary embolism developed a dental abscess. He was prescribed amoxicillin/clavulanate 500/125 mg twice daily and referred to a dentist. He underwent an uncomplicated outpatient tooth extraction after five days of antibiotic therapy. On the second day after the procedure, he noticed bleeding from the extraction site. On the third day, the bleeding worsened; he called his dentist and was seen urgently at the dentist’s office. Exploration of the surgical site demonstrated bleeding without hematoma formation. Several additional sutures were placed, the site was packed with gauze, and he was instructed to hold pressure if further bleeding developed. On day five, heavy bleeding returned, he noticed hematuria, and extensive bruising on his right forearm. He called his primary care physician (PCP) who instructed him to urgently contact his dentist and have his prothrombin time (PT) and international normalized ratio (INR) checked. His PT was 145 seconds, INR was 20.4. His dentist placed several more sutures and the patient was referred to the emergency room.
He had been taking warfarin 2 mg on Monday, Wednesday and Friday and 1 mg Tuesday, Thursday, Saturday, and Sunday for the past 20 years for chronic anticoagulation. His goal INR was in the range of 2.0–3.0, most recent INR less than one week prior to the procedure was 2.3. Figure 1 displays his INR trend over the preceding several months. His other medical problems include COPD, chronic non-union of his calcaneus following fracture, anxiety, and depression. He takes inhaled albuterol as needed, trazodone 50 mg po at bedtime, chlordiazepoxide 10 mg po 1 to 3 times a day and vicodin ES 7.5/750 1tab po as needed for pain. There had not been any recent change to his medications.
In the emergency room, his vital signs were stable, exam revealed bleeding from the extraction site and large bruises on the forearms bilaterally. Initial lab work showed Hb 13.7 g/dL, Hct 39.6%, WBC 8,100/mcL, and platelet count of 230,000/mcL. Serum electrolytes, renal function, liver function, thyroid function were all in the normal range. Repeat INR was 15.3, urinalysis demonstrated microscopic hematuria, and stool sample was guaiac positive. He received 4 units of fresh frozen plasma and 10 mg of vitamin K IV. Warfarin was held. The patient was admitted for close observation.
The bleeding from the extraction site resolved. His INR the next day was 1.3. Warfarin therapy was reinitiated and he was discharged home with enoxaparin 100mg subcutaneous daily for 5 days and oral warfarin at his prior dose. His INR one week after discharge was 2.3.
Discussion
The anticoagulant effect of warfarin is mediated through inhibition of the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X [5]. Almost all antibiotics have the theoretical potential to interact with Warfarin [6]. The apparent mechanism is related to a pharmacodynamic interaction via reductionin intestinal flora with subsequent reduced intrinsic vitamin K production leading to decreased vitamin K absorption. Additional mechanisms include antibiotic induced malabsorption of vitamin K and inhibition of cytochrome p450 isozymes, which reduces warfarin metabolisim [7]. Quinolones, sulfonamides, macrolides, and azole antifungals carry the highest risk of Warfarin toxicity [8–10].
Although penicillins have not consistently been shown to interact with warfarin [11], isolated cases have been reported, particularly with broad-spectrum penicillins. Narrow-spectrum penicillins are generally presumed to be safe provided the patients’ vitamin K intake is normal [12]. In a double-blind, crossover, placebo-controlled study Zhang et al demonstrated that amoxicillin/clavulanate did not alter INR in 12 patients on stable warfarin therapy who were given amoxicillin/clavulanate, of note these patients did not have active infection or inflammation [13]. There are, however, several case reports and retrospective reviews implicating amoxicillin/clavulanate as a cause of increased INR and/or increased risk of bleeding (Table 1).
We reviewed the potential interactions between our patient’s other medications and warfarin. Although acetaminophen has the potential to interact with warfarin [18], the patient had been taking acetaminophen intermittently for many years, had not recently increased his acetaminophen dose, and had never experienced major fluctuations in his INR. The temporal relationship between the administration of amoxicillin/clavulanate and development of supratherapeutic INR with bleeding implicate amoxicillin/clavulanate as the culprit. The Naranjo probability scale identifies our case as a probable adverse drug reaction [19].
The primary factor influencing the risk of bleeding is intensity of anticoagulation, the risk of major bleeding (e.g., intracranial, retroperitoneal, gastrointestinal) has been reported to increase when the INR is greater than 4.0 [20,21]. Hemorrhagic complications increase steeply when the INR is greater than 5.0.
The management of patients with warfarin toxicity depends on the level of INR and the presence or absence of clinically significant bleeding. Recommendation set forth by the American College of Chest Physicians include indications for both vitamin K and blood products (such as fresh frozen plasma) (Table 2) [22].
Conclusions
While rare, clinically significant increased INR and potentially life threatening bleeding can occur when amoxicillin/clavulanate is concomitantly administered with warfarin. Prompt recognition and intervention is necessary to avoid life threatening complications from warfarin-amoxicillin/clavulanate interaction.
References:
1. Jacobs LG, Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly: Clin Geriatr Med, 2005; 22; 17-32, pmid: 16377465
2. Holbrook AM, Pereira JA, Labiris R, Systematic overview of warfarin and its drug and food interactions: Arch Intern Med, 2005; 165; 1095-106, pmid: 15911722
3. Penning-van Beest F, Erkens J, Petersen KU, Main comedications associated with major bleeding during anticoagulant therapy with coumarins: Eur J ClinPharmacol, 2005; 61; 439-44
4. Freedman MD, Olatidoye AG, Clinically significant drug interactions with the oral anticoagulants: Drug Safety, 1994; 10(5); 381-94, pmid: 8037888
5. Freedman MD, Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects: J Clin Pharmacol, 1992; 32(3); 196-209, pmid: 1564123
6. Rice PJ, Perry RJ, Afzal Z, Stockley IH, Antibacterial prescribing and warfarin: a review: Br Dent J, 2003; 194(8); 411-15, pmid: 12778089
7. Kaminsky LS, Zhang ZY, Human P450 metabolism of warfarin: Pharmacol Thera, 1997; 73(1); 67-74
8. Schelleman H, Bilker WB, Brensinger CM, Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding: Clin Pharmacol Ther, 2008; 84(5); 581-88, pmid: 18685566
9. Glasheen JJ, Fugit RV, Prochazka AV, The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens: J Gen Inter Med, 2005; 20(7); 653-56
10. Baillargeon J, Holmes HM, Lin YL, Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults: Am J Med, 2012; 125(2); 183-89, pmid: 22269622
11. , A multicentre survey of antibiotics on the INR of anticoagulated patients: Pharm J (Pharmacy Practice Suppl), 1996; 257; R30, Buckley
12. Buckley NA, Dawson AH, Drug interactions with warfarin: Med J Austr, 1992; 157; 479-83
13. Zhang Q, Simoneau G, Verstuyft C, Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial: Br J Clin Pharmacol, 2011; 71(2); 232-36, pmid: 21219403
14. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW, Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses: Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1996; 82(6); 610-12, pmid: 8974131
15. Davydov L, Yermolnik M, Cuni LJ, Warfarin and amoxicillin/clavulanate drug interaction: The Ann Pharmacother, 2003; 37(3); 367-70
16. Kelly M, Moran J, Byrne S, Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: a case report: Am J Geriatr Pharmacother, 2005; 3(4); 266-69, pmid: 16503323
17. Wood GD, Deeble T, Warfarin: dangers with antibiotics: Dent Update, 1993; 20(8); 350-52, pmid: 8056109
18. Shek KL, Chan LN, Nutescu E, Warfarin-acetaminophen drug interaction revisited: Pharmacotherapy, 1999; 19; 1153-58, pmid: 10512064
19. Naranjo CA, Busto U, Sellers EM, A method for estimating the probability of adverse drug reactions: Clin Pharmacol, 1981; 30; 239
20. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL, The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation: Pharmacoepidemiol Drug Saf, 2002; 11(7); 569-76, pmid: 12462133
21. Ansell J, Hirsh J, Poller L, The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Chest, 2004; 126(3 Suppl.); 204S-33S, pmid: 15383473
22. Ansell J, Hirsh J, Hylek E, Pharmacology and management of the vita-min K antagonists: Chest, 2008; 133(Suppl.6); 160S-98S, pmid: 18574265
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






